EUVIMEDEUVIMED entdecken
Open Access

Multi-armored allogeneic MUC1 CAR T cells enhance efficacy and safety in triple-negative breast cancer

Piril Erler iD, Tomasz Kurcon, Hana Cho iD, Jordan Skinner iD, Chantel Dixon, Steven Grudman iD, Sandra Rozlan, Emilie Dessez, Ben Mumford, Sumin Jo iD, Alex Boyne iD, Alexandre Juillerat iD und 3 weitere

Science Advances · 30.08.2024 · 10 (35)

DOI: 10.1126/sciadv.adn9857 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 30.08.2024. Verfasst von Piril Erler und 14 weiteren Autor:innen. Beteiligte Einrichtung: Cellectis Inc., New York, NY, USA. Hauptthemen laut MEDLINE: Mucin-1, Triple Negative Breast Neoplasms, Receptors, Chimeric Antigen, Tumor Microenvironment. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Solid tumors, such as triple-negative breast cancer (TNBC), are biologically complex due to cellular heterogeneity, lack of tumor-specific antigens, and an immunosuppressive tumor microenvironment (TME). These challenges restrain chimeric antigen receptor (CAR) T cell efficacy, underlining the importance of armoring. In solid cancers, a localized tumor mass allows alternative administration routes, such as intratumoral delivery with the potential to improve efficacy and safety but may compromise metastatic-site treatment. Using a multi-layered CAR T cell engineering strategy that allowed a synergy between attributes, we show enhanced cytotoxic activity of MUC1 CAR T cells armored with PD1 KO , tumor-specific interleukin-12 release, and TGFBR2 KO attributes catered towards the TNBC TME. Intratumoral treatment effectively reduced distant tumors, suggesting retention of antigen-recognition benefits at metastatic sites. Overall, we provide preclinical evidence of armored non-alloreactive MUC1 CAR T cells greatly reducing high TNBC tumor burden in a TGFB1- and PD-L1–rich TME both at local and distant sites while preserving safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mucin-1Triple Negative Breast NeoplasmsReceptors, Chimeric AntigenTumor MicroenvironmentImmunotherapy, AdoptiveHumansFemaleAnimalsMiceCell Line, TumorT-LymphocytesXenograft Model Antitumor Assays

Substanzen

Mucin-1Receptors, Chimeric AntigenMUC1 protein, human

Autor:innen und Institutionen

  • Cellectis Inc., New York, NY, USA.
  • Cellectis SA, Paris, France.

ORCID-Profile: Piril Erler, Hana Cho, Jordan Skinner, Steven Grudman, Sumin Jo, Alex Boyne, Alexandre Juillerat, Philippe Duchateau, Beatriz Aranda-Orgilles

Zitieren

APA

Erler, P., Kurcon, T., Cho, H., Skinner, J., Dixon, C., Grudman, S., Rozlan, S., Dessez, E., Mumford, B., Jo, S., Boyne, A., Juillerat, A., Duchateau, P., Poirot, L., & Aranda-Orgilles, B. (2024). Multi-armored allogeneic MUC1 CAR T cells enhance efficacy and safety in triple-negative breast cancer. Science Advances, 10(35). https://doi.org/10.1126/sciadv.adn9857

Vancouver

Erler P, Kurcon T, Cho H, Skinner J, Dixon C, Grudman S, et al. Multi-armored allogeneic MUC1 CAR T cells enhance efficacy and safety in triple-negative breast cancer. Science Advances. 2024;10(35). doi:10.1126/sciadv.adn9857

BibTeX
@article{Erler2024,
  author = {Erler, Piril and Kurcon, Tomasz and Cho, Hana and Skinner, Jordan and Dixon, Chantel and Grudman, Steven and Rozlan, Sandra and Dessez, Emilie and Mumford, Ben and Jo, Sumin and Boyne, Alex and Juillerat, Alexandre and Duchateau, Philippe and Poirot, Laurent and Aranda-Orgilles, Beatriz},
  title = {Multi-armored allogeneic MUC1 CAR T cells enhance efficacy and safety in triple-negative breast cancer},
  journal = {Science Advances},
  year = {2024},
  volume = {10},
  number = {35},
  doi = {10.1126/sciadv.adn9857}
}
Kostenlos starten →